International Journal of Advances in Nursing Management

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Niemann-Pick Disease:The Genetic Condition and Nursing Consideration


Affiliations
1 Department of Medical Surgical Nursing, SDM Institute of Nursing Sciences, Sattur, Dharwad, 580009, Karnataka, India
     

   Subscribe/Renew Journal


Niemann-Pick Disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. There are three most common types of disease namely Niemann-Pick Types A, B and C. Niemann-Pick disease type C is an inherited condition in which the body cannot properly metabolize cholesterol and fats, resulting in an excess of these substances in the body. Approximately 95% of Niemann–Pick type C cases are caused by Genetic mutations in the NPC1 gene, referred to as type C1. The most common symptoms are, hepatomegaly, splenomegaly, prolonged neonatal jaundice, ataxia, clumsiness or frequent falls, dysphagia, gelastic cataplexy, myoclonus and deafness. Miglustat is the only disease-specific oral therapy approved to treat progressive neurological manifestation of NP-C.

Keywords

Niemann-Pick Disease, Lysosome, Mutation, Gene, Cataplexy.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Marc Patterson, MD Mayo Clinic Rochester, Minnesota Initial Posting: January 26, 2000; Last Update: July 18, 2013.

  • https://www.counsyl.com/services/family-prep-screen/diseases/niemann-pick-disease-type-c/

  • Alzheimer’s Society UK, Rarer Causes of Dementia Factsheet http://www.alzheimer.ca/~/media/Files/national/Otherdementias/rarer_dementias_niemann_pick_e.pdf

  • Marc C. Patterson, M.D. For Medical Professionals Clinical updates. http://www.mayoclinic.org/medical-professionals/clinical-updates/neurosciences/treating-rare-disease-niemann-pick-disease-type-c

  • Patterson MC, Vanier MT, et. all: Niemann-Pick disease type C: a lipid trafficking disorder. The Metabolic and Molecular Bases of Inherited Disease New York: Edited by: McGrawHillScriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, 8, 2001, 3611-3634.

  • Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA. 1999, 281: 249-254.10.1001/jama.281.3.249.

  • Wenger DA, Barth G, Githens JH: Nine cases of sphingomyelinlipidosis, a new variant in Spanish-American Children. Juvenile variant of Niemann-Pick Disease with foamy and sea-blue histiocytes. Am J Dis Child. 1977, 131: 955-961.

  • Available from-http://nnpdf.org/the-disease/diagnosis/

  • Mellon SH, Gong W, Schonemann MD (March 2008). "Endogenous and synthetic neurosteroids in treatment of Niemann–Pick Type C disease". Brain Research Reviews57 (2):410–20. Available fromhttps://www.counsyl.com/services/family-prepscreen/diseases/niemann-pick-disease-type-c/

  • Wraith JE, Imrie J. Understanding Niemann-Pick disease type C and its potential treatment. UK Blackwell Publishing, 2007.

  • Patterson MC. A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C Neurologist 2003; 9: 301-10.

  • Vanier MT. Niemann-Pick disease type C Orphanet J Rare Dis 2010; 5:16.

  • Mukherjee S, Maxfield FR. Lipid and cholesterol trafficking in NPC BiochimBiophysActa 2004; 1685: 28-37.

  • Patterson MC, Hendriksz CJ, Walterfang M, et al, on behalf of the NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update. Mol Genet Metab 2012. 106(3):330-344.

  • HannaAlobaidy. Hindawi Publishing Corporation International Journal of Pediatrics Volume 2015, Article ID 816593, 10 pages. Recent Advances in the Diagnosis and Treatment of NiemannPick Disease Type C in Children: A Guide to Early Diagnosis for the General Pediatrician

  • Marc Patterson, MD Mayo Clinic Rochester, Minnesota Initial Posting: January 26, 2000; Last Update: July 18, 2013.

  • Kandt RS, Emerson RG, Singer HS, Valle DL, Moser HW. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol. 1982 12((3)): 284-8.)

  • N.H.Pipalia, C. C. Cosner, A. Huangetal, “Histonedeacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol.108, no.14, pp.5620–5625, 2011.

  • M.T.Vanier,“Niemann-Pick disease type C,”Orphanet Journal of RareDiseases,vol.5,no.1,article16,2010

  • Saneifard H. MD. Iran J Child Neurol. 2015 Autumn vol 9 no 4 suppl.1

  • Available from-http://nnpdf.org/genetic-counseling/


Abstract Views: 213

PDF Views: 0




  • Niemann-Pick Disease:The Genetic Condition and Nursing Consideration

Abstract Views: 213  |  PDF Views: 0

Authors

Ananda Kudari
Department of Medical Surgical Nursing, SDM Institute of Nursing Sciences, Sattur, Dharwad, 580009, Karnataka, India

Abstract


Niemann-Pick Disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. There are three most common types of disease namely Niemann-Pick Types A, B and C. Niemann-Pick disease type C is an inherited condition in which the body cannot properly metabolize cholesterol and fats, resulting in an excess of these substances in the body. Approximately 95% of Niemann–Pick type C cases are caused by Genetic mutations in the NPC1 gene, referred to as type C1. The most common symptoms are, hepatomegaly, splenomegaly, prolonged neonatal jaundice, ataxia, clumsiness or frequent falls, dysphagia, gelastic cataplexy, myoclonus and deafness. Miglustat is the only disease-specific oral therapy approved to treat progressive neurological manifestation of NP-C.

Keywords


Niemann-Pick Disease, Lysosome, Mutation, Gene, Cataplexy.

References